ductal carcinoma

Summary

Summary: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.

Top Publications

  1. doi Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?
    Genevieve Soucy
    Department of Surgical Oncology, Maisonneuve Rosemont Hospital, University of Montreal, Montreal, Quebec, Canada
    J Am Coll Surg 206:1116-21. 2008
  2. ncbi Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy
    Aleix Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Head Neck 30:680-3. 2008
  3. ncbi Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:396-400. 2006
  4. ncbi Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas
    Jorge Albores-Saavedra
    Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA
    Ann Diagn Pathol 11:3-9. 2007
  5. pmc Ductal carcinoma in situ of the breast, a population-based study of epidemiology and pathology
    A Kricker
    School of Public Health, Level 6, Medical Foundation Building K25, University of Sydney NSW 2006, Australia
    Br J Cancer 90:1382-5. 2004
  6. pmc Study of matrix metalloproteinases and their inhibitors in breast cancer
    F J Vizoso
    Servicio de Cirugia General, Hospital de Jove, Gijon, Spain
    Br J Cancer 96:903-11. 2007
  7. ncbi DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma
    E L H Lui
    Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, Pokfulam
    Biomed Pharmacother 59:S363-5. 2005
  8. ncbi Ductal carcinoma arising from syringocystadenoma papilliferum in the external auditory canal
    Rodney C Diaz
    Department of Otolaryngology Head and Neck Surgery, University of California Davis Medical Center, Sacramento, California 95817, USA
    Otol Neurotol 28:873-4. 2007
  9. pmc Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast
    Min Hu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:3372-7. 2009
  10. doi Extent and histologic pattern of atypical ductal hyperplasia present on core needle biopsy specimens of the breast can predict ductal carcinoma in situ in subsequent excision
    Michael J Wagoner
    Department of Pathology and Cell Biology, University of South Florida College of Medicine, USA
    Am J Clin Pathol 131:112-21. 2009

Detail Information

Publications271 found, 100 shown here

  1. doi Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?
    Genevieve Soucy
    Department of Surgical Oncology, Maisonneuve Rosemont Hospital, University of Montreal, Montreal, Quebec, Canada
    J Am Coll Surg 206:1116-21. 2008
    ..The purpose of this study was to compare surgical margin involvement of breast-conservation resection specimens from patients treated initially with operation with those from patients receiving neoadjuvant chemotherapy...
  2. ncbi Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy
    Aleix Prat
    Department of Medical Oncology, Vall d Hebron University Hospital, Barcelona, Spain
    Head Neck 30:680-3. 2008
    Salivary ductal carcinoma (SDC) is an uncommon malignant tumor of the salivary glands...
  3. ncbi Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:396-400. 2006
    ..expression of established histopathologic and biologic markers of proliferation, apoptosis, and angiogenesis in invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in a group of axillary node-negative breast cancers.
  4. ncbi Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas
    Jorge Albores-Saavedra
    Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 71130, USA
    Ann Diagn Pathol 11:3-9. 2007
    ..Six patients died as a direct result of the carcinomas, and 1 was lost to follow-up. More studies are needed to determine the biologic behavior of this distinctive histologic variant of ductal adenocarcinoma of the pancreas...
  5. pmc Ductal carcinoma in situ of the breast, a population-based study of epidemiology and pathology
    A Kricker
    School of Public Health, Level 6, Medical Foundation Building K25, University of Sydney NSW 2006, Australia
    Br J Cancer 90:1382-5. 2004
    In a population-based series of 2109 women with ductal carcinoma in situ (DCIS) diagnosed in 1995-2000 in New South Wales, Australia, incidence increased by an average of 5...
  6. pmc Study of matrix metalloproteinases and their inhibitors in breast cancer
    F J Vizoso
    Servicio de Cirugia General, Hospital de Jove, Gijon, Spain
    Br J Cancer 96:903-11. 2007
    ....
  7. ncbi DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma
    E L H Lui
    Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, Pokfulam
    Biomed Pharmacother 59:S363-5. 2005
    ..This study focused on the hypermethylation status of the TIMP3 gene with clinical parameters in invasive breast ductal carcinoma (IDC) samples.
  8. ncbi Ductal carcinoma arising from syringocystadenoma papilliferum in the external auditory canal
    Rodney C Diaz
    Department of Otolaryngology Head and Neck Surgery, University of California Davis Medical Center, Sacramento, California 95817, USA
    Otol Neurotol 28:873-4. 2007
  9. pmc Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast
    Min Hu
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:3372-7. 2009
    ..previously described that fibroblasts promote, whereas normal myoepithelial cells inhibit, the progression of ductal carcinoma in situ (DCIS) to invasive breast carcinomas by using a xenograft model of human DCIS...
  10. doi Extent and histologic pattern of atypical ductal hyperplasia present on core needle biopsy specimens of the breast can predict ductal carcinoma in situ in subsequent excision
    Michael J Wagoner
    Department of Pathology and Cell Biology, University of South Florida College of Medicine, USA
    Am J Clin Pathol 131:112-21. 2009
    ..We found that ADH present in more than 2 foci in CNB specimens was a strong predictor of ductal carcinoma in situ (DCIS) on excision (>2 foci, 16/41 vs 6/82 for 1 or 2 foci; P < .0001)...
  11. pmc Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast
    Giorgio Zavagno
    Clinica Chirurgica II, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
    BMC Cancer 5:28. 2005
    ..This procedure has been recently proposed as part of the treatment for patients with ductal carcinoma in situ (DCIS), because cases of undetected invasive foci and nodal metastases occasionally occur...
  12. ncbi Secretory carcinoma of the breast: a distinct variant of invasive ductal carcinoma assessed by comparative genomic hybridization and immunohistochemistry
    Raihanatou Diallo
    Institute of Pathology, Heinrich Heine University, Dusseldorf, Germany
    Hum Pathol 34:1299-305. 2003
    ..These results support the hypothesis that SCAs have immunohistochemical and genetic features that distinguish them from IDCs of the usual type...
  13. ncbi Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion
    Yun Ge Zhao
    Department of Chemistry and Biochemistry and Institute of Molecular Biophysics, Florida State University, Tallahassee, Florida, USA
    Cancer Res 64:590-8. 2004
    ..membrane is an indispensable prerequisite for the initiation of invasion and the conversion of human breast ductal carcinoma in situ (DCIS) to infiltrating ductal carcinoma (IDC)...
  14. pmc Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
    Yunn Yi Chen
    Department of Surgery, University of California San Francisco, San Francisco, USA
    BMC Cancer 9:285. 2009
    Endocrine therapy is commonly recommended in the adjuvant setting for patients as treatment for ductal carcinoma in situ (DCIS)...
  15. doi Hidradenoma papilliferum with a ductal carcinoma in situ component: case report and review of the literature
    Marina Vazmitel
    Department of Pathology, Academy of Medical Postgraduate Education of Belarus, Minsk, Republic of Belarus
    Am J Dermatopathol 30:392-4. 2008
    ..Malignant change in HP is extremely rare. Only a single case of ductal carcinoma in situ arising in HP has been previously reported...
  16. ncbi Large mammary hamartoma with focal invasive ductal carcinoma
    Suneet K Pervatikar
    Department of Pathology, SDMCMSH, Dharwad, India
    Indian J Pathol Microbiol 52:249-51. 2009
    ..Fine needle aspiration cytology showed features of invasive ductal carcinoma along with normal benign glands that were mistaken for normal breast tissue...
  17. ncbi Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone
    Ioannis Mylonas
    Ludwig Maximilians University Munich, 1st Department of Obstetrics and Gynecology, 80337 Munich, Germany
    Anticancer Res 25:1719-23. 2005
    ....
  18. ncbi Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ
    Ruria Namba
    Department of Pathology and Laboratory Medicine, School of Medicine, University of California Davis, Sacramento, California 95817, USA
    Mol Cancer Res 2:453-63. 2004
    A transplantable model of human ductal carcinoma in situ that progresses to invasive carcinoma was developed from a genetically engineered mouse (GEM)...
  19. doi The role of sentinel node biopsy in ductal carcinoma in situ of the breast
    K Polom
    First Surgical Oncology and General Surgery Department, Wielkopolska Oncology Centre, Poznan, Poland
    Eur J Surg Oncol 35:43-7. 2009
    ..alternative to lymphadenectomy in the case of invasive breast carcinoma, although the sentinel node's role in ductal carcinoma in situ (DCIS) diagnosed on core needle biopsy has not been well defined nevertheless guidelines recommend ..
  20. ncbi Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme
    Jenny McCann
    Cancer Intelligence Unit, Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge, Strangeways Research Laboratory, Wort s Causeway, Cambridge CB1 8RN
    J Med Screen 11:117-25. 2004
    ....
  21. doi The sentinel lymph node procedure for patients with preoperative diagnosis of ductal carcinoma in situ: risk factors for unsuspected invasive disease and for metastatic sentinel lymph nodes
    R Sakr
    AP HP, Hopital Tenon, Department of Gynecology, Paris Cedex, France
    Int J Clin Pract 62:1730-5. 2008
    Occult invasive disease could be found at definitive histology in patients initially diagnosed with large ductal carcinoma in situ (DCIS)...
  22. ncbi Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ
    M Silvina Frech
    Lombardi Comprehensive Cancer Center, Departments of Oncology and Pathology, Georgetown University, 3970 Reservoir Road, Washington, DC 20057, USA
    Cancer Res 65:681-5. 2005
    ..alpha expression in mammary epithelial cells developed ductal hyperplasia (DH), lobular hyperplasia, and ductal carcinoma in situ (DCIS) by 4 months of age...
  23. ncbi Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast
    Pooi Pooi Leong
    Department of Clinical Laboratory Sciences, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 Seri Kembangan, Selangor, Malaysia
    Immunol Lett 102:229-36. 2006
    ..lymphocytes (TILs) from 47 enzymatically dissociated tumour specimens from patients with infiltrating ductal carcinoma (IDC) of the breast...
  24. pmc An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ
    Fariba Behbod
    Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
    Breast Cancer Res 11:R66. 2009
    ..b>Ductal carcinoma in situ (DCIS) is the most common type (80%) of noninvasive breast lesions...
  25. ncbi Ductal carcinoma arising from a syringocystadenoma papilliferum in a nevus sebaceus of Jadassohn
    Heino Hugel
    Dermatohispathologische Gemeinschaftspraxis, Friedrichshafen, Germany
    Am J Dermatopathol 25:490-3. 2003
    We present an example of ductal carcinoma connected to a syringocystadenoma papilliferum situated in a nevus sebaceus of Jadassohn on the scalp of a 22-year-old woman...
  26. ncbi ITIH5, a novel member of the inter-alpha-trypsin inhibitor heavy chain family is downregulated in breast cancer
    Marina Himmelfarb
    metaGen Pharmaceuticals GmbH, Oudenarder Str 16, 13347 Berlin, Germany
    Cancer Lett 204:69-77. 2004
    ..epithelial cells clearly express ITIH5, expression is consistantly lost or strongly downregulated in invasive ductal carcinoma. ITIH5 mRNA was neither detectable in cancerous nor benign breast cell lines...
  27. ncbi Alterations in the expression of PDCD4 in ductal carcinoma of the breast
    Yong Hannah Wen
    Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
    Oncol Rep 18:1387-93. 2007
    ..We observed primarily nuclear localization of PDCD4 in ductal carcinoma in situ compared to normal breast tissues where the PDCD4 expression was predominantly cytoplasmic...
  28. pmc Clinicopathological characteristics of mucinous carcinoma of the breast in Korea: comparison with invasive ductal carcinoma-not otherwise specified
    Seho Park
    Department of Surgery, Yonsei University College of Medicine, Seoul, Korea
    J Korean Med Sci 25:361-8. 2010
    ..characteristics and prognostic factors of mucinous carcinoma (MC) were compared with invasive ductal carcinoma-not otherwise specified (IDC-NOS)...
  29. ncbi Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas
    Shuichi Mitsunaga
    Pathology Division, National Cancer Center Research Institution East, 6 3 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
    Cancer Sci 96:858-65. 2005
    For clinicians, the orthodox histological investigation of patients with invasive ductal carcinoma (IDC) remains important for predicting prognoses...
  30. ncbi Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma
    Kazuaki Shimada
    Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo 104 0045, Japan
    Pancreas 33:233-9. 2006
    Recent advances in diagnostic modalities have made it possible to detect small pancreatic ductal carcinoma and to increase the number of resected cases. However, the postoperative prognosis remains dismal.
  31. doi Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ
    C Desmetz
    Department of Cellular Biology, CHU Montpellier, Hopital Arnaud de Villeneuve, Montpellier, France
    J Proteome Res 7:3830-7. 2008
    ..autoantibodies directed against this protein in the sera of 240 individuals, comprising patients with either ductal carcinoma in situ (DCIS) ( n = 49) or early stage breast cancer ( n = 58), other cancers ( n = 20), autoimmune disease (..
  32. ncbi Prognostic value of microvessel density in invasive ductal carcinoma of the breast
    Shinichi Tsutsui
    Department of Breast Surgery, Beppu National Hospital, 1473 Oaza Uchikamado, Beppu 874 0011, Japan
    Breast Cancer 10:312-9. 2003
    ..Although the prognostic value of microvessel density (MVD) has been studied in breast cancer, the results still remain controversial...
  33. ncbi Immunohistochemical evaluation of vasopressin expression in breast fibrocystic disease and ductal carcinoma in situ (DCIS)
    William G North
    Department of Physiology, Dartmouth Medical School, Lebanon, NH 03756 0001, USA
    Endocr Pathol 14:257-62. 2003
    ..Alternatively, we examined 16 cases of breast ductal carcinoma in situ (DCIS) using the second of these antibodies (anti-VAG), and all of these cases were positive for ..
  34. ncbi Cytologic findings and protein expression profiles associated with ductal carcinoma of the breast in ductal lavage specimens using surface-enhanced laser desorption and ionization-time of flight mass spectrometry
    Savvas Mendrinos
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia 30322, USA
    Cancer 105:178-83. 2005
    ....
  35. pmc Expression analysis of carbohydrate antigens in ductal carcinoma in situ of the breast by lectin histochemistry
    Soheila Korourian
    Winthrop P, Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    BMC Cancer 8:136. 2008
    The number of breast cancer patients diagnosed with ductal carcinoma in situ (DCIS) continues to grow. Laboratory and clinical data indicate that DCIS can progress to invasive disease...
  36. doi Pure ductal carcinoma in situ: a range of MRI features
    Sughra Raza
    Department of Radiology, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    AJR Am J Roentgenol 191:689-99. 2008
    ..and illustrate the variety of common morphologic features, enhancement patterns, and kinetics of pure ductal carcinoma in situ (DCIS) on dynamic contrast-enhanced MRI of the breast, using the American College of Radiology BI-..
  37. ncbi Scirrhous colonic metastasis from ductal carcinoma of the breast: report of a case
    Wai Lun Law
    Department of Surgery, Queen Mary Hospital, University of Hong Kong Medical Centre, Hong Kong, China
    Dis Colon Rectum 46:1424-7. 2003
    ..The histologic diagnosis is consistent with colonic metastasis from ductal carcinoma of breast origin...
  38. ncbi Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast
    Yasuhiro Miki
    Department of Pathology, Tohoku University Graduate School of Medicine, 2 1 Seiryo machi, Aoba ku, Sendai, Miyagi ken 980 8575, Japan
    J Steroid Biochem Mol Biol 114:68-71. 2009
    ..through intratumoral production in an intracrine manner, play important roles in the development of invasive ductal carcinoma (IDC) of human breast, but biological and/or clinical significance of intratumoral production and metabolism ..
  39. ncbi Screening of genes specifically activated in the pancreatic juice ductal cells from the patients with pancreatic ductal carcinoma
    Koji Yoshida
    Division of Functional Genomics, Jichi Medical School, Kawachi gun, Tochigi
    Cancer Sci 94:263-70. 2003
    Pancreatic ductal carcinoma (PDC) is one of the most intractable human malignancies. Surgical resection of PDC at curable stages is hampered by a lack of sensitive and reliable detection methods...
  40. ncbi Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: the two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses
    Karim Chahed
    Laboratoire d Immuno Oncologie Moleculaire, Faculte de medecine de Monastir, Tunisia
    Int J Oncol 27:1425-31. 2005
    In the present study, total proteins from a tissue of an infiltrating ductal carcinoma of the breast (IDCA) were compared by the two-dimensional electrophoresis (2D-PAGE) to proteins from an adjacent non-neoplastic breast tissue...
  41. ncbi The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters
    Rui Juan Gao
    Institute of Genetics and Cytology, School of Life Sciences, Northeast Normal University, Changchun, Jilin Province, PR China
    Breast Cancer Res Treat 93:111-5. 2005
    ..One hundred and forty-four patients with invasive ductal carcinoma of breast were involved in this study...
  42. doi Diagnosis of ductal carcinoma in situ using contrast-enhanced magnetic resonance mammography compared with conventional mammography
    Tibor Vag
    Institute of Diagnostic and Interventional Radiology, Friedrich Schiller University Jena, Erlanger Allee 101, 07747 Jena, Germany
    Clin Imaging 32:438-42. 2008
    The objective of this study is to compare mammography with magnetic resonance mammography (MRM) in the diagnosis of histopathologically verified subtypes of ductal carcinoma in situ (DCIS).
  43. ncbi A case of anaplastic ductal carcinoma of the pancreas with production of granulocyte-colony stimulating factor
    Naoto Gotohda
    Department of Hepatobiliary Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan
    Hepatogastroenterology 53:957-9. 2006
    We report a case of anaplastic ductal carcinoma of the pancreas with production of granulocytecolony stimulating factor in a 46-year-old man...
  44. ncbi Contrast-enhanced MRI of ductal carcinoma in situ: characteristics of a new intensity-modulated parametric mapping technique correlated with histopathologic findings
    Michelle N Mariano
    Department of Radiology, Stanford University Medical Center, Stanford, California, USA
    J Magn Reson Imaging 22:520-6. 2005
    To identify morphologic and dynamic enhancement magnetic resonance imaging (MRI) features of pure ductal carcinoma in situ (DCIS) by using a new intensity-modulated parametric mapping technique, and to correlate the MRI features with ..
  45. ncbi Chromosome 8 numerical aberrations in stage II invasive ductal carcinoma: correlation with patient outcome and poor prognosis
    Yutaka Tagawa
    School of Health Sciences, Nagasaki University, Nagasaki City, Nagasaki 852 8102, Japan
    Med Oncol 20:127-36. 2003
    ..Our results suggest that the frequencies of chromosome 8 gain and disomy is a potentially useful parameter for predicting prognosis of stage II IDCs...
  46. ncbi Breast cancer in patients with prior augmentation: presentation, stage, and lymphatic mapping
    James W Jakub
    Lakeland Regional Cancer Center Lakeland, Fla 33805, USA
    Plast Reconstr Surg 114:1737-42. 2004
    ..This initial mode of detection does not appear to translate into a larger tumor size or worse prognosis. Breast conservation and lymphatic mapping can be performed successfully in previously augmented patients...
  47. ncbi Tubulolobular carcinoma of the breast: an analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile
    Darren T Wheeler
    Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology, Washington, DC 20306 6000, USA
    Am J Surg Pathol 28:1587-93. 2004
    ..The prognosis of these tumors appears to be excellent, especially in those cases that are unilateral and less than 2 cm in size...
  48. ncbi Management of bilateral breast carcinoma: long-term results
    Husnu A Goksel
    Department of General Surgery, Baskent University Faculty of Medicine, Ankara, Turkey
    Int Surg 89:166-71. 2004
    ..The premenopausal women had a significantly longer mean lactation period. Extended lactation may be a risk factor for breast cancer development in this age group, but this needs further investigation...
  49. ncbi Axillary ultrasound scanning in the follow-up of breast cancer patients undergoing sentinel node biopsy
    Tommaso Susini
    Department of Gynecology, Perinatology and Human Reproducton, University of Florence, Italy
    Breast 16:190-6. 2007
    ..We conclude that routine AUS to follow-up patients who have had a negative SNB is unnecessary. However, AUS may be useful in the presence of palpable nodes, to select those patients who do not require biopsy...
  50. ncbi Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer
    Maria Giselle Peters
    Area Investigacion, Instituto de Oncologia Angel H Roffo, C1417DTB Buenos Aires, Argentina
    Oncol Rep 12:1143-50. 2004
    ..We demonstrated that several regulators of cell cycle progression were altered in a large number of breast tumor cases, however, these abnormalities were not indicators of a worse outcome in breast cancer patients of stages I and II...
  51. ncbi Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients
    Outi Kilpivaara
    Department of Obstetrics and Gynecology, Helsinki University Central Hospital, FIN 00029 HUS, Finland
    Int J Cancer 113:575-80. 2005
    ..02). The c.1100delC germ line mutation also associated strongly with bilateral breast cancer. No significant correlation was seen between CHEK2 status and hormone receptor status, histology, lymph node status, or overall survival...
  52. ncbi Oncoplastic resection of retroareolar breast cancer: central quadrantectomy and reconstruction by local skin-glandular flap
    Sherif F Naguib
    The Department of Surgical Oncology, National Cancer Institute, Cairo University
    J Egypt Natl Canc Inst 18:334-47. 2006
    ..With the help of Oncoplastic Surgical Techniques, BCS can be offered to these patients. In this study central quadrantectomy and breast reconstruction by an infero-laterally based pedicled flap were evaluated...
  53. doi Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up
    Lee K Tan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 26:1803-9. 2008
    ..However, there is no consensus regarding the optimal method for pathologic examination of SLN, or the prognostic significance of SLN micrometastases...
  54. ncbi Prognostic value of syndecan-1 expression in breast cancer
    Marja Leivonen
    Department of Surgery, Peijas Hospital, Helsinki University Central Hospital, Vantaa, Finland
    Oncology 67:11-8. 2004
    ..The objective of this study was to evaluate the prognostic value of the immunohistochemical expression of syndecan-1 in a series of 200 patients with invasive breast cancer with a median follow-up of 17 years...
  55. ncbi HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma
    Sharon A Oldford
    Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St John s, Newfoundland, Canada
    Int J Cancer 112:399-406. 2004
    ....
  56. doi Aberrant expression of E-cadherin in lobular carcinomas of the breast
    Leonard Da Silva
    Molecular and Cellular Pathology, Mayne Medical School, University of Queensland, Brisbane, Australia
    Am J Surg Pathol 32:773-83. 2008
    ..Positive staining for E-cadherin should not preclude a diagnosis of lobular in favor of ductal carcinoma. Molecular evidence suggests that even when E-cadherin is expressed, the cadherin-catenin complex maybe ..
  57. ncbi Touch prep cytology as a preferred approach for evaluating sentinel lymph nodes in breast cancer
    M Lisa Attebery
    Breast J 13:106-7. 2007
  58. ncbi Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse
    Gaynor J Bates
    Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital Cancer Research UK Molecular Oncology Laboratory, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
    J Clin Oncol 24:5373-80. 2006
    ..To assess the clinical significance of tumor-infiltrating FOXP3-positive regulatory T cells (TR) in breast cancer patients with long-term follow-up...
  59. ncbi Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women
    Heather Spencer Feigelson
    Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia 30329, USA
    Cancer 107:12-21. 2006
    ..Although the link between postmenopausal breast cancer and adiposity is well established, the association between weight gain and specific histopathologic characteristics of breast carcinoma has not been studied carefully...
  60. ncbi A novel mobile device for intraoperative radiotherapy (IORT)
    U Kraus-Tiefenbacher
    Abteilung für Radiologie, Department of Radiation Oncology, Universitatsklinikum Mannheim, Universitat Heidelberg, Mannheim, Germany
    Onkologie 26:596-8. 2003
  61. ncbi Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer
    Sandra J Roddiger
    Radiation Department, Klinikum Offenbach, Germany
    Strahlenther Onkol 182:22-9. 2006
    ..The goal was to evaluate the type of surgical treatment, histopathologic response, side effects, local control, and survival...
  62. ncbi Glucocorticoid receptor changes its cellular location with breast cancer development
    Isabel Conde
    Department of Cell Biology and Genetics, University of Alcala, Alcala de Henares, Madrid Spain
    Histol Histopathol 23:77-85. 2008
    ..Thus, breast cancer progression is associated with the accumulation of GR in the cytoplasm of tumoral cells and the decrease of COX-2 expression...
  63. ncbi Identifying patients at risk of compromised margins following breast conservation for lobular carcinoma
    Mary F Dillon
    Department of Surgery, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Am J Surg 191:201-5. 2006
    ..We sought to identify patients at risk of compromised margins following breast conservation surgery...
  64. ncbi Intraoperative radiotherapy (IORT) with 50-kv X-ray machines as boost in breast cancer -- more questions than answers
    Vratislav Strnad
    Onkologie 29:73-5. 2006
  65. ncbi Intraoperative radiotherapy (IORT) as a boost in patients with early-stage breast cancer -- acute toxicity
    Uta Kraus-Tiefenbacher
    Department of Radiation Oncology, Universitatsklinikum Mannheim, Germany
    Onkologie 29:77-82. 2006
    ..We report on acute toxicities as well as the early cosmetic outcome of patients receiving intraoperative radiotherapy (IORT) followed by whole-breast radiotherapy (WBRT) compared to patients treated with standard WBRT alone...
  66. ncbi Postmastectomy radiotherapy in intermediate risk stage I-II breast cancer patients
    J Mladenovic
    Department of Radiotherapy, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
    J BUON 12:215-20. 2007
    ....
  67. ncbi Early mammographic and sonographic findings after intraoperative radiotherapy (IORT) as a boost in patients with breast cancer
    K Wasser
    Department of Radiology, University Hospital Mannheim, University of Heidelberg, Heidelberg, Germany
    Eur Radiol 17:1865-74. 2007
    ..There is no evidence that the interpretation of findings is complicated after IORT...
  68. doi Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells
    F C Bidard
    Department of Medical Oncology, Institut Curie, Paris, France
    Ann Oncol 19:496-500. 2008
    ..Detection of disseminated tumor cells (DTC) in bone marrow (BM) is an independent prognostic factor in early breast cancer. We evaluated the prognostic value of DTC detection in the BM of metastatic breast cancer patients...
  69. ncbi Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes
    E Dikicioglu
    Department of Pathology, Adnan Menderes University, Medical School, Aydin, Turkey
    Int J Clin Pract 59:1039-44. 2005
    ..05). This study suggested that ALN metastasis might indicate a more unfavourable expression pattern of ER, PgR and Ki-67 in invasive ductal breast cancer...
  70. ncbi A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC)
    Ali Shamseddine
    Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
    Am J Clin Oncol 28:393-8. 2005
    ..This report is a pilot study assessing the antitumor efficacy and safety of this regimen as first line therapy for advanced breast cancer patients...
  71. pmc In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin
    A Batistatou
    Department of Pathology, University of Ioannina Medical School, P O Box 1186, Ioannina 45110, Greece
    Br J Cancer 96:1404-8. 2007
    ..We have selected ductal carcinoma, which is by far the most common type and lobular carcinoma, which has a distinctive microscopic appearance...
  72. ncbi Recurrence rates and analysis of close or positive margins in patients treated without re-excision before radiation for breast cancer
    Alyson McIntosh
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am J Clin Oncol 30:146-51. 2007
    ..This study examines the risk of local recurrence in a group of patients accepted for radiation therapy after breast-conserving surgery despite having a close or positive resection margin...
  73. ncbi Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
    Giampietro Gasparini
    Medical Oncology Division, San Filippo Neri Hospital, Unità Operativa Complessa di Oncologia Medica, Azienda Complesso Ospedaliero di Rilevanza Nazionale S Filippo Neri, Via G Martinotti, 20 00135 Rome, Italy
    Breast Cancer Res Treat 101:355-65. 2007
    ..A randomized Phase II study evaluated the activity of weekly paclitaxel versus its combination with trastuzumab for treatment of patients with advanced breast cancer overexpressing HER-2...
  74. ncbi Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue
    Sylvia Aust
    Center for Physiology and Pathophysiology, Medical University of Vienna, AKH, Waehringer Guertel 18 20, A 1020 Vienna, Austria
    Int J Oncol 26:1079-85. 2005
    ....
  75. ncbi Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy
    Eeva Rahko
    Departments of Oncology, University of Oulu, Oulu University Hospital, Finland
    Anticancer Res 24:4247-53. 2004
    ..We examined, here, whether the MMP-9 immunoreactive protein would correlate with--the prognosis in breast carcinoma treated with hormonal adjuvant therapy...
  76. ncbi Bilateral synchronous breast cancer. A clinical dilemma
    Salman Y Guraya
    The Division of General Surgery, Department of Surgery, College of Medicine and King Khalid University Hospital, King Saud University, PO Box 286896, Riyadh 11323, Kingdom of Saudi Arabia
    Saudi Med J 25:2024-5. 2004
  77. ncbi A pilot study of wider use of accelerated partial breast irradiation: intraoperative margin-directed re-excision combined with sole high-dose-rate interstitial brachytherapy
    Takayuki Nose
    Department of Radiation Oncology, Cancer Institute Hospital, 3 10 6 Ariake, Koto ku, Tokyo 135 8550, Japan
    Breast Cancer 13:289-99. 2006
    ..with conventional radiotherapy achieved an excellent 10-year local control rate of 93%, and young age and ductal carcinoma in situ were not risk factors for local recurrence...
  78. ncbi Relationship between age maximum height is attained, age at menarche, and age at first full-term birth and breast cancer risk
    Christopher I Li
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M4 C308, P O Box 19024, Seattle, WA 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 16:2144-9. 2007
    ....
  79. ncbi Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery
    Channikarn Changsri
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Breast J 10:392-7. 2004
    ..Primary tumor characteristics did not correlate with the incidence of NSLN metastasis in our series...
  80. ncbi HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays
    T K Yau
    Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
    Hong Kong Med J 14:130-5. 2008
    ....
  81. ncbi Blood hemoglobin level and treatment outcome of early breast cancer
    Michael Henke
    Department of Radiotherapy, Radiological University Clinic, University Freiburg, Germany
    Strahlenther Onkol 180:45-51. 2004
    ..To determine whether the blood hemoglobin concentration correlates with the prognosis of patients with early breast cancer and, if so, whether this is restricted to treatment modality...
  82. ncbi [Clinical usefulness and perspectives of sentinel node biopsy in the management of breast cancer]
    A Haid
    Landeskrankenhaus Feldkirch, Akademisches Lehrkrankenhaus der Universität Innsbruck, Feldkirch, Voralberg
    Chirurg 74:657-64. 2003
    ..The aim of this study was to show that SNB alone must have a place in routine clinical work and is reliable after preoperative chemotherapy (PC) and also in patients with multicentric tumors (MC)...
  83. pmc Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?
    P Chollet
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Br J Cancer 89:1185-91. 2003
    ....
  84. ncbi Extracapsular extension in positive axillary lymph nodes in female breast cancer patients. Patterns of failure and indications for postoperative locoregional irradiation
    Heidi Stranzl
    Department of Radiotherapy, University Medical School, Graz, Austria
    Strahlenther Onkol 180:31-7. 2004
    ..There has been little information regarding lymph node-positive breast cancer patients with extracapsular extension (ECE). The aim of this study was to evaluate the role of ECE in predicting survival and relapse rates...
  85. ncbi HLA-G is a potential tumor marker in malignant ascites
    Gad Singer
    Department of Pathology, Johns Hopkins University Medical Institutions, Baltimore Maryland 21231, USA
    Clin Cancer Res 9:4460-4. 2003
    ..HLA-G is a potential tumor-associated marker and that one of its isoforms, HLA-G5, produces a secretory protein. This study is to assess the clinical utility of secreted HLA-G levels in differential diagnosis of malignant ascites...
  86. ncbi Do we need HER-2/neu testing for all patients with primary breast carcinoma?
    Susanne Taucher
    Department of Surgery, Vienna University Medical School, Vienna, Austria
    Cancer 98:2547-53. 2003
    ..The objective of the current study was to investigate the probability, calculated using parameters that are assessed routinely in clinical practice, that patients with breast carcinoma had positive HER-2/neu status...
  87. ncbi [Metastatic breast cancer in the uterine cervix: two cases of a rare occurrence]
    Ottó Lehoczky
    Országos Onkológiai Intézet, Nógyógyászati Onkológiai Osztálya, Budapest
    Orv Hetil 144:1637-8. 2003
    ..The final diagnoses was proved by cervical conisation in the first patient and by hysterectomy in the second one. Authors call attention for the possibility of the rare site of symptom free recurrence...
  88. ncbi Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma
    Ramachandran Prasad
    Department of Surgery, University Hospital of South Manchester, Manchester, United Kingdom
    Cancer 98:2539-46. 2003
    ..The goal of rhe current study was to determine the short-term effect of HRT withdrawal on invasive breast carcinoma using biologic surrogate markers of tumor response...
  89. pmc Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion
    Yan Gao Man
    Department of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC, USA
    Breast Cancer Res 5:R231-41. 2003
    ..This is in contrast to the adjacent cells within the same duct, which were strongly immunoreactive for the ER. The current study attempts to confirm and expand previous observations on a larger scale...
  90. ncbi Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells
    Alice Hemsen
    Institute for Tumor Biology, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20251 Hamburg, Germany
    Int J Cancer 107:903-9. 2003
    ..Our results indicate that uPAR plays an active role in breast cancer metastasis and may therefore be a promising target for new biologic therapies...
  91. ncbi DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma
    Mary Jo Fackler
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 401 N Broadway, Baltimore, MD 21231 2410, USA
    Int J Cancer 107:970-5. 2003
    ..01). These results suggest that these 2 types of tumors share many common methylation patterns and some molecular differences. Additional studies might lend further understanding into the etiology and clinical behavior of this tumor type...
  92. doi Epithelial atypia: a marker risk of concomitant or subsequent breast carcinoma?
    Isabelle de Mascarel
    J Clin Oncol 26:4514-5; author reply 4515. 2008
  93. ncbi Thioredoxin is associated with proliferation, p53 expression and negative estrogen and progesterone receptor status in breast carcinoma
    Nina Turunen
    Department of Pathology, Oulu University Hospital, Oulu, Finland
    APMIS 112:123-32. 2004
    ....
  94. doi Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer
    F Puglisi
    Department of Clinical Oncology, University Hospital of Udine, Piazzale S M Misericordia, 33100 Udine, Italy
    Ann Oncol 19:1541-6. 2008
    ..Furthermore, we explored the relationship between TP tumor expression and benefit from this regimen...
  95. ncbi Measurement of somatostatin receptor subtype 2 mRNA in breast cancer and corresponding normal tissue
    C Orlando
    Clinical Biochemistry Unit, Department of Clinical Physiopathology, University of Florence, Florence, Italy
    Endocr Relat Cancer 11:323-32. 2004
    ..Featuring a possible role of somatostatin analogs in combined endocrine therapies for breast cancer, our results seem to confirm that the sst2 status of the tumor should be previously investigated...
  96. ncbi Bilateral reduction mammoplasty in combination with lumpectomy for treatment of breast cancer in patients with macromastia
    Eugene Chang
    Oregon Health and Science University, Portland, OR, USA
    Am J Surg 187:647-50; discussion 650-1. 2004
    ..Bilateral reduction mammoplasty has been described as a surgical option for treatment of breast cancer in women with large, pendulous breasts. Using this technique can provide unique surgical oncologic challenges...
  97. ncbi Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer
    Ute Woelfle
    Institute of Tumor Biology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 10:2670-4. 2004
    ..Cytokeratins (CKs) have been recognized for >20 years as structural marker proteins specific for epithelial cells. Recent expression profiling analyses indicate, however, that CK down-regulation may occur in breast cancer...
  98. ncbi Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study
    Roland Reitsamer
    Department of Senology, General Hospital, Salzburg, Austria
    Strahlenther Onkol 180:38-44. 2004
    ....
  99. ncbi Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue
    Peter T Simpson
    The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    J Pathol 202:274-85. 2004
    ..Strong expression of 14-3-3sigma was evident in one case of ductal carcinoma in situ (5.5%) and in 105/554 invasive cancers (18.9%)...
  100. ncbi Validation of axillary sentinel lymph node detection in the staging of early lobular invasive breast carcinoma: a prospective study
    Jean Marc Classe
    Department of Oncological Surgery, Rene Gauducheau Cancer Center, Saint Herblain, France
    Cancer 100:935-41. 2004
    ....
  101. ncbi Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer
    Lorraine O'Driscoll
    National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
    Cancer Lett 201:225-36. 2003
    ....

Research Grants68

  1. Interplay Between Tissue Architecture and Nuclear Organization in the DNA Damage
    Pierre Alexandre Vidi; Fiscal Year: 2013
    ..A 3D culture model of ductal carcinoma in situ will be used to test if altering mechanical or biochemical BM signaling leads to decreased DSB repair ..
  2. Developing miRNA diagnostic methods and identifying tumor regulatory networks
    Thomas Tuschl; Fiscal Year: 2010
    ..The specimen collection includes 80 triple negative, 51 HER2 positive, 26 ER positive, 11 normal and 20 ductal carcinoma in situ (DCIS) samples...
  3. Ecd as a regulator of cell cycle and breast oncogenesis
    Vimla Band; Fiscal Year: 2013
    ..Notably, Ecd is overexpressed in breast cancer cell lines as well as in ductal carcinoma in situ and infiltrating ductal carcinomas of the breast...
  4. Clinical Study of Disposition and Biological Activity of d-Limonene
    H H Sherry Chow; Fiscal Year: 2010
    ..bioavailability of d- limonene and its associated biological activities in women with a recent diagnosis of ductal carcinoma in situ, lobular carcinoma in situ, or atypical ductal hyperplasia elected to undergo excision surgery...
  5. Development and Validation of a Panel of Breast Cancer for the Early Diagnosis of
    FELIX RODOLFO FERNANDEZ MADRID; Fiscal Year: 2010
    ..This will be accomplished by using sera from women with ductal carcinoma in situ (DCIS) of the breast for cloning the new antigens, and by selecting cloning sera containing ..
  6. Defining the role of Amot lipid binding in cellular proliferation and migration
    ANN CAROL KIMBLE-HILL; Fiscal Year: 2013
    ..Statistically, individuals with hyperplasia are 3-5 times more likely to develop breast cancer, and ductal carcinoma makes up approximately 80% of all breast cancer cases...
  7. Measuring signaling pathway dynamics during tissue growth in hydrogels
    Lonnie D Shea; Fiscal Year: 2013
    ..with invasive breast cancer, and in 50% estrogen receptor (ER) negative and 12% of ER positive cases of ductal carcinoma in situ...
  8. A her-2/neu Pulsed DC1 Vaccine for Patients with DCIS
    BRIAN JOSEPH CZERNIECKI; Fiscal Year: 2012
    ..MHC class I and class II peptides derived from HER-2/neu administered in a neoadjuvant trial to patients with ductal carcinoma in situ (DCIS) resulted in near uniform sensitization of HER-2/neu specific CD4, and CD8 T cells, induction ..
  9. Smoothened function as a G-Protein Coupled Receptor in mammary epithelial cells
    Hugo Villanueva; Fiscal Year: 2013
    ..Smoothened (SMO), a critical component of the Hh pathway, is overexpressed in about 70% of ductal carcinoma in situ (DCIS), and about 30% of invasive breast cancer...
  10. Radiation and Genomic Instability in Finite Lifespan Human Mammary Epithelium
    Amy Kronenberg; Fiscal Year: 2010
    ..that genomic instability first appears in human breast biopsy materials at the earliest malignant stage - ductal carcinoma in situ - suggesting that instability is an important early feature in the development of breast cancer...
  11. miRNA Biomarkers from FFPE Tissue for Early Breast Cancer Detection
    Sidney W Fu; Fiscal Year: 2013
    ..They are ductal epithelial hyperplasia (DEH), atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS)...
  12. Vermont Center on Behavior and Health
    Stephen T Higgins; Fiscal Year: 2013
    ..Breast Cancer Survivors;(5) Brian Sprague, PhD, Behaviors, Chronic Disease, and Quality of Life After Ductal Carcinoma In Situ...
  13. Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
    Celina G Kleer; Fiscal Year: 2012
    ..and on IGF-1 signaling in vivo using unique human tissue resources consisting of samples of normal breast, ductal carcinoma in situ (DCIS), invasive carcinomas, and nodal and distant metastases...
  14. Manipulating b1 integrin to enhance radiation therapy for breast cancer
    Catherine C Park; Fiscal Year: 2012
    ..signaling mediates a survival signal via Akt using 3D IrECM culture models of invasive breast cancer and ductal carcinoma in situ (DCIS) and to expand upon the Akt-mediated survival effects of Beta1 integrin signaling post-IR in ..
  15. The Role of CCN5 in Progression of Breast Cancer
    Sushanta K Banerjee; Fiscal Year: 2013
    ..Furthermore, preliminary studies suggest that CCN5 may inhibit the transition of in situ ductal carcinoma (DCIS) to invasive BC through the protection of biological fences (myoepithelial layer and basement membrane),..
  16. MRI of Early Non-invasive Rodent Mammary Cancers
    Gregory S Karczmar; Fiscal Year: 2013
    ..We will study mouse mammary intra-epithelial neoplasia (MIN);this early, non-invasive neoplasia is very similar to ductal carcinoma in situ, or DCIS, in humans.
  17. Mechanisms of action of the Smyd3 methyltransferase in cancer cells
    Julien Sage; Fiscal Year: 2013
    ..elevated in tumors with oncogenic RAS, we will focus on mouse models of lung adenocarcinoma and pancreas ductal carcinoma, two fatal human cancers in which the RAS pathway is often activated...
  18. Multicenter Genetic, Epigenetic &Expression Analysis of DCIS outcome predictors
    Christopher B Umbricht; Fiscal Year: 2013
    ..The goal of this project is to identify the molecular alterations that occur in the progression from ductal carcinoma in situ (DCIS) to invasive breast cancer...
  19. A tool for analysis of gene-specific DNA methylation in clinical samples
    Victor V Levenson; Fiscal Year: 2010
    ..To confirm the utility of the tool, biomarkers for detection of invasive breast cancer and ductal carcinoma in situ will be developed...
  20. Syndecan-1 in Stromal Fibroblasts of Breast Carcinomas
    Andreas Friedl; Fiscal Year: 2013
    ..Aim 2: Analyze the role of Sdc1 and ECM architecture in the progression from ductal carcinoma in situ (DCIS) to invasive carcinoma...
  21. Stem cells and their aberrant self-renewal pathways in DCIS malignant progression
    Kelli E Valdez; Fiscal Year: 2013
    ..b>Ductal carcinoma in situ (DCIS) is a non-invasive cancer lesion that progresses to invasive cancer approximately half the time...
  22. Role of EZH2 in Breast Cancer Progression
    Celina G Kleer; Fiscal Year: 2013
    ..funding cycle, we have demonstrated that EZH2 protein is upregulated during progression from normal breast to ductal carcinoma in situ, the precursor of invasive carcinoma, to invasive carcinoma, being highest at the metastasis...
  23. Digital Pathology_Accuracy Viewing Behavior and Image Characterization
    DONALD LEE WEAVER; Fiscal Year: 2013
    ..and likely lead to altered patient treatment, especially at the thresholds of atypical hyperplasia and ductal carcinoma in situ, where up to 50% of cases are misclassified...
  24. Proteasome-mediated Degradation of Hematopoietic Progenitor Kinase 1 in Pancreati
    Huamin Wang; Fiscal Year: 2012
    ..demonstrated that HPK1 protein is expressed in normal pancreatic ducts, but is lost in >95% of pancreatic ductal carcinoma (PDC) samples...
  25. C/EBPb Modulates Macrophages and Tumor-Initiating Cells During Preneoplastic Prog
    Heather L Machado; Fiscal Year: 2013
    ..Gene profiling studies of both pre-malignant DCIS (ductal carcinoma in situ) and invasive breast cancer have resulted in the classification of various subtypes, which largely ..
  26. C/EBPb Modulates Macrophages and Tumor-Initiating Cells During Preneoplastic Prog
    Heather L Machado; Fiscal Year: 2012
    ..Gene profiling studies of both pre-malignant DCIS (ductal carcinoma in situ) and invasive breast cancer have resulted in the classification of various subtypes, which largely ..
  27. Progression of DCIS to invasive breast cancer through CCR2 chemokine signaling
    Nikki Cheng; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Ductal carcinoma in situ (DCIS) is the most common type of non-invasive breast cancer diagnosed in women and an immediate precursor to invasive ductal carcinoma (IDC)...
  28. miR-140 and Breast Cancer Prevention
    Qun Zhou; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Patients with ductal carcinoma in situ (DCIS) have significant risks of developing recurrence or invasive breast cancer even after they receive breast surgery...
  29. Prevention & Metastasis: Final Frontiers in Colon Cancer
    Robert Coffey; Fiscal Year: 2009
    ..Finally, we are continuing efforts to model pancreatic ductal carcinoma in the mouse...
  30. Small Molecule Antibody Mimics: Toward a New Paradigm in Targeted Cancer Therapy
    David A Spiegel; Fiscal Year: 2013
    ..both in prostate cancer cells and in tumor neovasculature for a wide variety of cancers (including pancreatic ductal carcinoma, colon adenocarcinoma, glioblastoma multiforme, and non-small cell lung carcinoma)...
  31. Proteolytic Pathways in Progression of Pre-Malignant Breast Disease
    Bonnie F Sloane; Fiscal Year: 2013
    Mammographic screening leads to many women being diagnosed with ductal carcinoma in situ [DCIS], yet we cannot accurately predict which lesions will undergo malignant progression to invasive ductal carcinomas [IDC] or effectively block ..
  32. Costs and Complications of Radiotherapy Modalities
    Heather Taffet Gold; Fiscal Year: 2012
    ..the costs and complications of two radiotherapy (RT) techniques used for early invasive breast cancer and ductal carcinoma in situ (DCIS)...
  33. CpG Island Methylator Phenotypes in Breast Cancer
    Tim H M Huang; Fiscal Year: 2011
    ..model that simulates the history of methylation alteration from pre-neoplastic lesions to hyperplasia to ductal carcinoma in situ to invasive cancers...
  34. A Novel Plasminogen Receptor in Breast Cancer
    BARBARA MARIA MUELLER; Fiscal Year: 2013
    ..Our preliminary data show that Plg-RKT is highly expressed in human invasive ductal carcinoma and metastatic human breast tumor cell lines...
  35. Quantitative Mechanical Imaging for Improving Breast Ultrasound Diagnosis
    Timothy J Hall; Fiscal Year: 2013
    ..Third, measurements of ex vivo breast tissue samples found that ductal carcinoma in situ (DCIS) has the highest elastic nonlinearity of all tissues considered...
  36. Effectiveness of Pre-Operative MRI in Breast Cancer Surgery and Outcomes
    Tracy Onega; Fiscal Year: 2013
    ..of women primarily from community settings, enabling us to examine subgroups of women, such as those with ductal carcinoma in situ, dense breasts or family history of breast cancer, and to have greater generalizability than previous ..
  37. Accuracy of Breast Pathology and the Impact of Double Reading
    DONALD LEE WEAVER; Fiscal Year: 2013
    ..hyperplasia (ADH) in more than 50% of cases and a misclassification rate for cases designated by experts as ductal carcinoma in situ (DCIS) of 17%...
  38. Chemokine Receptor Modulation of the Tumor Microenvironment
    Oriana E Hawkins; Fiscal Year: 2012
    ..of the tumor microenvironment (TME) that interact with the inflammatory cells to mediate progression of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC)...
  39. Beta-Catenin/TCF Signaling in Breast Cancer
    Louise R Howe; Fiscal Year: 2012
    ..preliminary studies have revealed evidence of beta-catenin/TCF pathway activation in breast hyperplasias and ductal carcinoma in situ (DCIS) lesions, frequent precursors to invasive breast cancer...
  40. Continued Development and Evaluation of caTIES
    Rebecca S Crowley; Fiscal Year: 2013
    ..example, a researcher studying genetic variation in metastatic breast cancers can identify cases of invasive ductal carcinoma of the breast, followed by metastatic ductal cancer in bone at an interval of three years or greater from the ..
  41. Multi-marker prognostic profile to predict invasive progression in DCIS patients
    Steven P Linke; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. The lesions are typically surgically removed...
  42. Risk Factors for Second Primary Breast Cancer Among DCIS Survivors
    Christopher I Li; Fiscal Year: 2013
    ..to expand this work by evaluating factors that are related to risk of second primary breast cancers among ductal carcinoma in situ (DCIS) survivors. Incidence rates of DCIS have increased 7...
  43. SPORE IN BREAST CANCER
    SARA SUKUMAR; Fiscal Year: 2010
    ..Research Project 1 focuses on identification of molecular markers for progression of ductal carcinoma in situ, building on a successful research program for detecting epigenetic molecular markers...
  44. Characterizing the Evolution of Pre-malignant Tissues at High Risk for Malignancy
    THEA D contact TLSTY; Fiscal Year: 2010
    ..These markers identify a highly aggressive pre-malignant subtype that we call "basal-like" ductal carcinoma in situ (B-L DCIS) in this application since it shares markers specific to basal-like invasive tumors...
  45. Novel Tree-based Statistical Methods for Cancer Risk Prediction
    Annette M Molinaro; Fiscal Year: 2013
    ..A definitive example is mammography and ductal carcinoma in situ (DCIS), a noninvasive breast cancer...
  46. Myoepithelial cell differentiation defects in ductal carcinoma in situ (DCIS)
    Kornelia Polyak; Fiscal Year: 2013
    ..abstract_text> ..
  47. Analytical Investigation of Breast Cancer Progression: DCIS, Overdiagnosis
    Sandra J Lee; Fiscal Year: 2013
    ..The principal research areas include:(i) Develop a stochastic model for the disease progression of breast ductal carcinoma in situ (DCIS), (ii) Investigate the natural history of breast cancer, including methods for estimating the ..
  48. Invasive breast cancer with and without DCIS: Race, risk factors and outcomes
    PATRICIA ANN MASSO-WELCH; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): There has been little research conducted to determine if pure invasive ductal carcinoma (IDC) with no concomitant ductal carcinoma in situ (DCIS) differs from mixed IDC with DCIS in etiology, ..
  49. MRI For Staging DCIS and Assessing Response to Treatment
    Nola M Hylton; Fiscal Year: 2010
    b>Ductal carcinoma in situ (DCIS) is an early, pre-invasive form of breast cancer that conveys an excellent prognosis if local control is achieved...
  50. Vermont PROSPR Research Center (VPRC)
    Brian L Sprague; Fiscal Year: 2013
    ..process by developing prognostic markers that can be used to develop personalized management strategies for ductal carcinoma in situ (DCIS)...
  51. Green tea catechins in precancerorus prevention
    HWA CHAIN WANG; Fiscal Year: 2009
    ..Clinically, the transformed breast cells involved in ductal carcinoma-in-situ (DCIS) are precancerous and can either develop into or raise the risk of invasive breast cancer...
  52. Stromal activation in the progression of high ErbB2/1433zeta DCIS to IBC
    Dihua Yu; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Studying the transition from non-invasive ductal carcinoma in situ (DCIS) to life-threatening invasive breast cancer (IBC) is listed in the top quartile of the 100 research priorities by the Institute ..
  53. Hospital and County-Level Predictors of Immediate Breast Reconstruction Post-Mast
    CATHERINE ANN RICHARDS; Fiscal Year: 2012
    ..Inpatient Sample (NIS) on ~42,000 women who underwent mastectomy to treat invasive breast cancer or ductal carcinoma in situ (DCIS) will be combined with hospital-level data from the NIS, the American Hospital Association (AHA)..
  54. Validated Modeling and Culture of Salivary Cancers
    Wendell G Yarbrough; Fiscal Year: 2013
    ..otherwise specified, polymorphous low grade adenocarcinoma, carcinoma ex-pleomorphic adenoma, and salivary ductal carcinoma. We also propose to create cell lines from multiple histological types of salivary cancer using primary ..
  55. CANCER PREVENTION BY SELENIUM-ENRICHED ALLIUM VEGETABLES
    Clement Ip; Fiscal Year: 2003
    ..well documented that preneoplastic IDPs progressively develop into more advanced neoplastic lesions called "ductal carcinoma in situ" or DCIS...
  56. Addressing the Challenges in Transitioning from Mammography to Breast Tomosynthe*
    Mini Das; Fiscal Year: 2013
    ..very high rate of detectability for microcalcifications (MCs), which are the primary precursor for invasive ductal carcinoma (DCIS)...
  57. Impact of ErbB2 and RB Pathways on DCIS Progression and Treatment
    Agnieszka Witkiewicz; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Currently ductal carcinoma in situ (DCIS) accounts for 20-30% of newly diagnosed breast cancers in screened populations...
  58. A Video DVD Program to Assist with Informed Consent
    Neil Love; Fiscal Year: 2004
    ..The NSABP B-35 trial will randomize approximately 3,000 women with Ductal Carcinoma In Situ (DCIS) to either the nonsteroidal aromatase inhibitor, anastrozole or tamoxifen...
  59. Immune dysregulation by psychosocial distress
    HERBERT MATHEWS; Fiscal Year: 2006
    ..In the past decade, the number of women diagnosed with the form of breast cancer known as ductal carcinoma in situ (DCIS) has markedly increased...
  60. PNI and Decision Making in Women Diagnosed with DCIS
    LINDA JANUSEK; Fiscal Year: 2007
    ..The past decade has witnessed an increase in the number of women diagnosed with ductal carcinoma in situ (DCIS) due to the widespread use of screening mammography...
  61. ETIOLOGY OF EARLY BREAST MALIGNANCY
    E Greenberg; Fiscal Year: 1999
    ..It is clear, however, that the occurrence of in situ cancers, particularly ductal carcinoma in situ (DCIS), is an important step in the evaluation of some invasive breast cancers...
  62. MAMMOGRAPHIC DENSITY AND BREAST CANCER AFTER DCIS
    Laurel Habel; Fiscal Year: 2000
    The diagnosis of ductal carcinoma in situ (DCIS) of the breast has risen dramatically during the last two decades and now accounts for 10-15 percent of all breast cancers diagnosed in the US...
  63. IMMUNE RESPONSE TO BREAST DUCTAL CARCINOMA IN SITU
    Scott Pruitt; Fiscal Year: 1999
    ..If indicated by these initial studies, therapy directed against both the complement and NAb components of the response will be combined in an effort to further prolong xenograft survival. ..
  64. RISK FACTORS AND BIOMARKERS FOR IN SITU BREAST CANCER
    Linda Titus Ernstoff; Fiscal Year: 1999
    ..We will evaluate risk factors for BCIS and its major subtypes, lobular carcinoma in situ (LCIS), ductal carcinoma in sine (DCIS), and the aggressive DCIS subtype (comedo-type DCIS)...
  65. CYCLIN E EXPRESSION IN HUMAN CANCER
    Peggy Porter; Fiscal Year: 2002
    ..tissue samples from 913 young women diagnosed with invasive breast cancer and from 225 women diagnosed with ductal carcinoma in situ (DCIS) for expression of cyclin E and the cell cycle inhibitor p27 in the context of other tumor ..
  66. Cost-Effectiveness--Treatments--Ductal Carcinoma In Situ
    Jennifer Griggs; Fiscal Year: 2004
    The incidence of ductal carcinoma in situ (DCIS) of the breast, a non-invasive form of breast cancer, has increased dramatically in the last 15 years. Its burden both on patients and on society has grown correspondingly...
  67. Technology for Global and Quantitative Proteome Analysis
    Richard Smith; Fiscal Year: 2001
    ..determine relative protein abundances and phosphorylation states of proteomes relevant to breast cancer progression, including identifying distinctive protein profiles of ductal carcinoma in situ, tumor and normal breast epithelium.
  68. PROGNOSIS OF METASTATIC DISEASE IN EARLY BREAST CANCER
    Orhan Nalcioglu; Fiscal Year: 2005
    ..Provided by applicant): We propose to investigate the angiogenesis status in stage I and II invasive ductal carcinoma (IDC) of the breast by immunohistochemistry (IHC) and magnetic resonance imaging (MRI)...